A Multicenter, 47‐Month Study of Safety and Efficacy of Calcium Hydroxylapatite for Soft Tissue Augmentation of Nasolabial Folds and Other Areas of the Face

OBJECTIVES Each soft tissue filler product has its own unique profile in terms of adverse events. In this large‐scale study, we investigated the safety profile of Radiesse, an injectable calcium hydroxylapatite (CaHA) implant, in treatment of nasolabial folds and other areas of the face. We also inv...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Dermatologic surgery 2007-12, Vol.33, p.S122-S127
Hauptverfasser: SADICK, NEIL S., KATZ, BRUCE E., ROY, DEBORSHI
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S127
container_issue
container_start_page S122
container_title Dermatologic surgery
container_volume 33
creator SADICK, NEIL S.
KATZ, BRUCE E.
ROY, DEBORSHI
description OBJECTIVES Each soft tissue filler product has its own unique profile in terms of adverse events. In this large‐scale study, we investigated the safety profile of Radiesse, an injectable calcium hydroxylapatite (CaHA) implant, in treatment of nasolabial folds and other areas of the face. We also investigated the efficacy in a subset of the larger patient group. METHODS After obtaining informed consent from the subjects, researchers injected CaHA at two treatment centers into 113 patients (100 women and 13 men, ranging in age from 26 to 78 years) for a variety of facial aesthetic applications over a period of 47 months. Seventy‐five patients had a single injection session; 38 had multiple sessions. Most patients (102) received 1.0 mL of CaHA per session; 12 received 2.0 mL per session. Typically, CaHA was administered with a 27‐gauge 0.5‐ or 1 1/4‐in. needle. RESULTS Safety. Of 113 patients, only 7 reported minor adverse events that were short‐term and resolved within 1 month: transient ecchymosis (3), nongranulatomous submucosal nodules of the lip (2), and inflammation and edema (2). Efficacy. Efficacy ratings were performed for a subset of patients (n=41). On a scale of 1 to 5 (1=unsatisfactory; 5=excellent), the mean patient evaluation score for look and feel of the implant was 4.6; the mean physician scores for the look and feel of the implant were 4.5 and 4.6, respectively. During the 6‐month follow‐up visit, patients' mean ratings of the look and feel of the implant were 4.8 and 4.9, respectively. The physician's mean ratings for the look and feel of the implant were 4.5 and 4.9, respectively. CONCLUSIONS In our study, CaHA performed well, with a favorable safety profile, high patient satisfaction (90% of patients reported very good or excellent results), and good durability. We are especially pleased with the low incidence of adverse events coupled with the favorable responses from the patients themselves due to longevity of correction.
doi_str_mv 10.1111/j.1524-4725.2007.33351.x
format Article
fullrecord <record><control><sourceid>wiley_pubme</sourceid><recordid>TN_cdi_pubmed_primary_18086049</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>DSU33351</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3191-1bdc641213847b222f003c809fceca8abd913eaccd077d4e0a8f8d5b8c6d92b43</originalsourceid><addsrcrecordid>eNpFUctOwkAUnRiNIPoLZj7A1nn0uTEhCGICsiisJ7fzkJJCSTuNdOcn-AV-nF9iCz7u5j7OuWdxDkKYEpe2db9xqc88xwuZ7zJCQpdz7lP3cIb6f8B5O5MwcIhPWQ9dVdWGEMpiTi5Rj0YkCogX99HnEM_r3GZS76wu77AXfr1_zIudXePE1qrBhcEJGG0bDDuFx8ZkEuTxPIJcZvUWTxtVFocmhz3YzGpsihInhbF4mVVVrfGwft226i1Y7Lq_F6iKHNIMcjwpclUdhRd2rUs8LDVUHafd8ASkvkYXBvJK3_z0AVpNxsvR1Jktnp5Hw5kjOY2pQ1MlA48yyiMvTBljhhAuIxIbqSVEkKqYcg1SKhKGytMEIhMpP41koGKWenyAbk-6-zrdaiX2ZbaFshG_RrWEhxPhLct1848T0QUiNqLzXXS-iy4QcQxEHMRjsjqO_BvKaYFJ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Multicenter, 47‐Month Study of Safety and Efficacy of Calcium Hydroxylapatite for Soft Tissue Augmentation of Nasolabial Folds and Other Areas of the Face</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>Access via Wiley Online Library</source><creator>SADICK, NEIL S. ; KATZ, BRUCE E. ; ROY, DEBORSHI</creator><creatorcontrib>SADICK, NEIL S. ; KATZ, BRUCE E. ; ROY, DEBORSHI</creatorcontrib><description>OBJECTIVES Each soft tissue filler product has its own unique profile in terms of adverse events. In this large‐scale study, we investigated the safety profile of Radiesse, an injectable calcium hydroxylapatite (CaHA) implant, in treatment of nasolabial folds and other areas of the face. We also investigated the efficacy in a subset of the larger patient group. METHODS After obtaining informed consent from the subjects, researchers injected CaHA at two treatment centers into 113 patients (100 women and 13 men, ranging in age from 26 to 78 years) for a variety of facial aesthetic applications over a period of 47 months. Seventy‐five patients had a single injection session; 38 had multiple sessions. Most patients (102) received 1.0 mL of CaHA per session; 12 received 2.0 mL per session. Typically, CaHA was administered with a 27‐gauge 0.5‐ or 1 1/4‐in. needle. RESULTS Safety. Of 113 patients, only 7 reported minor adverse events that were short‐term and resolved within 1 month: transient ecchymosis (3), nongranulatomous submucosal nodules of the lip (2), and inflammation and edema (2). Efficacy. Efficacy ratings were performed for a subset of patients (n=41). On a scale of 1 to 5 (1=unsatisfactory; 5=excellent), the mean patient evaluation score for look and feel of the implant was 4.6; the mean physician scores for the look and feel of the implant were 4.5 and 4.6, respectively. During the 6‐month follow‐up visit, patients' mean ratings of the look and feel of the implant were 4.8 and 4.9, respectively. The physician's mean ratings for the look and feel of the implant were 4.5 and 4.9, respectively. CONCLUSIONS In our study, CaHA performed well, with a favorable safety profile, high patient satisfaction (90% of patients reported very good or excellent results), and good durability. We are especially pleased with the low incidence of adverse events coupled with the favorable responses from the patients themselves due to longevity of correction.</description><identifier>ISSN: 1076-0512</identifier><identifier>EISSN: 1524-4725</identifier><identifier>DOI: 10.1111/j.1524-4725.2007.33351.x</identifier><identifier>PMID: 18086049</identifier><language>eng</language><publisher>Malden, USA: Blackwell Publishing Inc</publisher><subject>Adult ; Aged ; Biocompatible Materials - administration &amp; dosage ; Biocompatible Materials - adverse effects ; Cosmetic Techniques ; Durapatite - administration &amp; dosage ; Durapatite - adverse effects ; Face ; Female ; Humans ; Injections ; Male ; Microspheres ; Middle Aged ; Treatment Outcome</subject><ispartof>Dermatologic surgery, 2007-12, Vol.33, p.S122-S127</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3191-1bdc641213847b222f003c809fceca8abd913eaccd077d4e0a8f8d5b8c6d92b43</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1524-4725.2007.33351.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1524-4725.2007.33351.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18086049$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SADICK, NEIL S.</creatorcontrib><creatorcontrib>KATZ, BRUCE E.</creatorcontrib><creatorcontrib>ROY, DEBORSHI</creatorcontrib><title>A Multicenter, 47‐Month Study of Safety and Efficacy of Calcium Hydroxylapatite for Soft Tissue Augmentation of Nasolabial Folds and Other Areas of the Face</title><title>Dermatologic surgery</title><addtitle>Dermatol Surg</addtitle><description>OBJECTIVES Each soft tissue filler product has its own unique profile in terms of adverse events. In this large‐scale study, we investigated the safety profile of Radiesse, an injectable calcium hydroxylapatite (CaHA) implant, in treatment of nasolabial folds and other areas of the face. We also investigated the efficacy in a subset of the larger patient group. METHODS After obtaining informed consent from the subjects, researchers injected CaHA at two treatment centers into 113 patients (100 women and 13 men, ranging in age from 26 to 78 years) for a variety of facial aesthetic applications over a period of 47 months. Seventy‐five patients had a single injection session; 38 had multiple sessions. Most patients (102) received 1.0 mL of CaHA per session; 12 received 2.0 mL per session. Typically, CaHA was administered with a 27‐gauge 0.5‐ or 1 1/4‐in. needle. RESULTS Safety. Of 113 patients, only 7 reported minor adverse events that were short‐term and resolved within 1 month: transient ecchymosis (3), nongranulatomous submucosal nodules of the lip (2), and inflammation and edema (2). Efficacy. Efficacy ratings were performed for a subset of patients (n=41). On a scale of 1 to 5 (1=unsatisfactory; 5=excellent), the mean patient evaluation score for look and feel of the implant was 4.6; the mean physician scores for the look and feel of the implant were 4.5 and 4.6, respectively. During the 6‐month follow‐up visit, patients' mean ratings of the look and feel of the implant were 4.8 and 4.9, respectively. The physician's mean ratings for the look and feel of the implant were 4.5 and 4.9, respectively. CONCLUSIONS In our study, CaHA performed well, with a favorable safety profile, high patient satisfaction (90% of patients reported very good or excellent results), and good durability. We are especially pleased with the low incidence of adverse events coupled with the favorable responses from the patients themselves due to longevity of correction.</description><subject>Adult</subject><subject>Aged</subject><subject>Biocompatible Materials - administration &amp; dosage</subject><subject>Biocompatible Materials - adverse effects</subject><subject>Cosmetic Techniques</subject><subject>Durapatite - administration &amp; dosage</subject><subject>Durapatite - adverse effects</subject><subject>Face</subject><subject>Female</subject><subject>Humans</subject><subject>Injections</subject><subject>Male</subject><subject>Microspheres</subject><subject>Middle Aged</subject><subject>Treatment Outcome</subject><issn>1076-0512</issn><issn>1524-4725</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFUctOwkAUnRiNIPoLZj7A1nn0uTEhCGICsiisJ7fzkJJCSTuNdOcn-AV-nF9iCz7u5j7OuWdxDkKYEpe2db9xqc88xwuZ7zJCQpdz7lP3cIb6f8B5O5MwcIhPWQ9dVdWGEMpiTi5Rj0YkCogX99HnEM_r3GZS76wu77AXfr1_zIudXePE1qrBhcEJGG0bDDuFx8ZkEuTxPIJcZvUWTxtVFocmhz3YzGpsihInhbF4mVVVrfGwft226i1Y7Lq_F6iKHNIMcjwpclUdhRd2rUs8LDVUHafd8ASkvkYXBvJK3_z0AVpNxsvR1Jktnp5Hw5kjOY2pQ1MlA48yyiMvTBljhhAuIxIbqSVEkKqYcg1SKhKGytMEIhMpP41koGKWenyAbk-6-zrdaiX2ZbaFshG_RrWEhxPhLct1848T0QUiNqLzXXS-iy4QcQxEHMRjsjqO_BvKaYFJ</recordid><startdate>200712</startdate><enddate>200712</enddate><creator>SADICK, NEIL S.</creator><creator>KATZ, BRUCE E.</creator><creator>ROY, DEBORSHI</creator><general>Blackwell Publishing Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>200712</creationdate><title>A Multicenter, 47‐Month Study of Safety and Efficacy of Calcium Hydroxylapatite for Soft Tissue Augmentation of Nasolabial Folds and Other Areas of the Face</title><author>SADICK, NEIL S. ; KATZ, BRUCE E. ; ROY, DEBORSHI</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3191-1bdc641213847b222f003c809fceca8abd913eaccd077d4e0a8f8d5b8c6d92b43</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Biocompatible Materials - administration &amp; dosage</topic><topic>Biocompatible Materials - adverse effects</topic><topic>Cosmetic Techniques</topic><topic>Durapatite - administration &amp; dosage</topic><topic>Durapatite - adverse effects</topic><topic>Face</topic><topic>Female</topic><topic>Humans</topic><topic>Injections</topic><topic>Male</topic><topic>Microspheres</topic><topic>Middle Aged</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SADICK, NEIL S.</creatorcontrib><creatorcontrib>KATZ, BRUCE E.</creatorcontrib><creatorcontrib>ROY, DEBORSHI</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Dermatologic surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SADICK, NEIL S.</au><au>KATZ, BRUCE E.</au><au>ROY, DEBORSHI</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Multicenter, 47‐Month Study of Safety and Efficacy of Calcium Hydroxylapatite for Soft Tissue Augmentation of Nasolabial Folds and Other Areas of the Face</atitle><jtitle>Dermatologic surgery</jtitle><addtitle>Dermatol Surg</addtitle><date>2007-12</date><risdate>2007</risdate><volume>33</volume><spage>S122</spage><epage>S127</epage><pages>S122-S127</pages><issn>1076-0512</issn><eissn>1524-4725</eissn><abstract>OBJECTIVES Each soft tissue filler product has its own unique profile in terms of adverse events. In this large‐scale study, we investigated the safety profile of Radiesse, an injectable calcium hydroxylapatite (CaHA) implant, in treatment of nasolabial folds and other areas of the face. We also investigated the efficacy in a subset of the larger patient group. METHODS After obtaining informed consent from the subjects, researchers injected CaHA at two treatment centers into 113 patients (100 women and 13 men, ranging in age from 26 to 78 years) for a variety of facial aesthetic applications over a period of 47 months. Seventy‐five patients had a single injection session; 38 had multiple sessions. Most patients (102) received 1.0 mL of CaHA per session; 12 received 2.0 mL per session. Typically, CaHA was administered with a 27‐gauge 0.5‐ or 1 1/4‐in. needle. RESULTS Safety. Of 113 patients, only 7 reported minor adverse events that were short‐term and resolved within 1 month: transient ecchymosis (3), nongranulatomous submucosal nodules of the lip (2), and inflammation and edema (2). Efficacy. Efficacy ratings were performed for a subset of patients (n=41). On a scale of 1 to 5 (1=unsatisfactory; 5=excellent), the mean patient evaluation score for look and feel of the implant was 4.6; the mean physician scores for the look and feel of the implant were 4.5 and 4.6, respectively. During the 6‐month follow‐up visit, patients' mean ratings of the look and feel of the implant were 4.8 and 4.9, respectively. The physician's mean ratings for the look and feel of the implant were 4.5 and 4.9, respectively. CONCLUSIONS In our study, CaHA performed well, with a favorable safety profile, high patient satisfaction (90% of patients reported very good or excellent results), and good durability. We are especially pleased with the low incidence of adverse events coupled with the favorable responses from the patients themselves due to longevity of correction.</abstract><cop>Malden, USA</cop><pub>Blackwell Publishing Inc</pub><pmid>18086049</pmid><doi>10.1111/j.1524-4725.2007.33351.x</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1076-0512
ispartof Dermatologic surgery, 2007-12, Vol.33, p.S122-S127
issn 1076-0512
1524-4725
language eng
recordid cdi_pubmed_primary_18086049
source MEDLINE; Journals@Ovid Complete; Access via Wiley Online Library
subjects Adult
Aged
Biocompatible Materials - administration & dosage
Biocompatible Materials - adverse effects
Cosmetic Techniques
Durapatite - administration & dosage
Durapatite - adverse effects
Face
Female
Humans
Injections
Male
Microspheres
Middle Aged
Treatment Outcome
title A Multicenter, 47‐Month Study of Safety and Efficacy of Calcium Hydroxylapatite for Soft Tissue Augmentation of Nasolabial Folds and Other Areas of the Face
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T02%3A19%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-wiley_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Multicenter,%2047%E2%80%90Month%20Study%20of%20Safety%20and%20Efficacy%20of%20Calcium%20Hydroxylapatite%20for%20Soft%20Tissue%20Augmentation%20of%20Nasolabial%20Folds%20and%20Other%20Areas%20of%20the%20Face&rft.jtitle=Dermatologic%20surgery&rft.au=SADICK,%20NEIL%20S.&rft.date=2007-12&rft.volume=33&rft.spage=S122&rft.epage=S127&rft.pages=S122-S127&rft.issn=1076-0512&rft.eissn=1524-4725&rft_id=info:doi/10.1111/j.1524-4725.2007.33351.x&rft_dat=%3Cwiley_pubme%3EDSU33351%3C/wiley_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18086049&rfr_iscdi=true